Dr. Daniel L. Silbergeld, MD

Dr. Silbergeld practices at Harborview Medical Center in Seattle, Washington, part of University of Washington.

Dr. Silbergeld's NPI, 1215089263, was assigned on January 18, 2007. Dr. Silbergeld graduated from University Of Cincinnati College Of Medicine in 1984. Dr. Silbergeld's Washington license number on file is MD00023519.

Dr. Silbergeld's primary practice is Harborview Medical Center, at 325 9th Avenue, Seattle, WA 98104 in King County. The practice phone is (206) 744-9535.

Dr. Silbergeld's primary practice is Harborview Medical Center in Seattle, Washington, part of University of Washington. Dr. Silbergeld is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians. Dmand AI also links Dr. Silbergeld to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Silbergeld practices, 4 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Silbergeld's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Silbergeld is board certified in neurological surgery by the American Board of Neurological Surgery. Dr. Silbergeld has a license on file in Washington.

Dmand AI lists craniotomy among the conditions Dr. Silbergeld treats.

CMS data shows 144 Medicare services from Dr. Silbergeld across 4 procedure codes in 2024, for 42 Medicare patients. Medicare paid $64,812 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 42 Medicare patients who saw Dr. Silbergeld in 2024. The largest group is 65 to 74, with 24 patients. 67% of them have high cholesterol, and 62% have high blood pressure. Their average risk score is 2.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Silbergeld's median patient age at 63, with 60% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Silbergeld for performance year 2024, reported through an alternative payment model (APM). Dr. Silbergeld accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 94 papers to Dr. Silbergeld, published from 2005 to 2023. 2012 was the busiest year, with 8. The most frequent topics are Brain Neoplasms, Glioblastoma and Magnetic Resonance Imaging. Dr. Silbergeld has published most often in Neurosurgery. Dr. Silbergeld's most frequent co-authors are Andrew Lin Ko, MD, Jeffrey G. Ojemann and Robert C. Rostomily.

Dmand AI links Dr. Silbergeld to 1 clinical trial. Conditions studied include Oligodendroglioma and Gliosarcoma.

CMS Open Payments shows 33 general payments to Dr. Silbergeld from 8 drug and device companies from 2016 to 2022. Food and beverage make up the largest share, 54% of the total. Synaptive Medical Inc. paid the most, $2,014.

Dmand AI lists 6 awards for Dr. Silbergeld, most recently America's Top Doctors in 2014.

Dr. Silbergeld graduated from University Of Cincinnati College Of Medicine in 1984. Dr. Silbergeld is a member of AANS, ACS and CNS.

Dr. Silbergeld is in network with 10 carriers, including Blue Cross Blue Shield of Michigan, Humana and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.